Harmony Biosciences Holdings Inc
General ticker "HRMY" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.9B
Harmony Biosciences Holdings Inc follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 2.3%: low 33.77$, high 35.35$
Factors to consider:
- US accounted for 100.0% of revenue in the fiscal year ended 2023-12-31
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [20.62$, 35.06$]
- 2024-12-30 to 2025-12-30 estimated range: [18.59$, 32.50$]
Financial Metrics affecting the HRMY estimates:
- Positive: 0.93 < Non-GAAP EPS, $ of 2.24
- Positive: Operating profit margin, % of 32.99 > 19.51
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.70 > 7.10
- Negative: Industry earnings per price (median), % of -15.01 <= 1.31
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: Industry inventory ratio change (median), % of -2.41 <= -0.39
- Positive: -0.96 < Investing cash flow per share, $ of -0.78
Short-term HRMY quotes
Long-term HRMY plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $305.44MM | $437.86MM | $582.02MM |
| Operating Expenses | $217.91MM | $317.67MM | $389.99MM |
| Operating Income | $87.53MM | $120.19MM | $192.03MM |
| Non-Operating Income | $-50.10MM | $-15.50MM | $-18.63MM |
| Interest Expense | $23.97MM | $15.67MM | $23.76MM |
| R&D Expense | $30.37MM | $70.89MM | $76.06MM |
| Income(Loss) | $37.43MM | $104.69MM | $173.40MM |
| Taxes | $2.83MM | $-76.78MM | $44.54MM |
| Profit(Loss) | $34.60MM | $181.47MM | $128.85MM |
| Stockholders Equity | $186.51MM | $402.84MM | $466.99MM |
| Inventory | $4.43MM | $4.30MM | $5.36MM |
| Assets | $433.44MM | $673.87MM | $811.45MM |
| Operating Cash Flow | $98.56MM | $144.47MM | $219.39MM |
| Capital expenditure | $100.30MM | $40.17MM | $0.31MM |
| Investing Cash Flow | $-100.30MM | $-141.83MM | $-46.44MM |
| Financing Cash Flow | $7.42MM | $6.84MM | $-105.55MM |
| Earnings Per Share* | $0.60 | $3.07 | $2.17 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.